Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial

BMC Gastroenterology

Table 4 Incidence of gastrointestinal symptoms

Gastrointestinal symptom	Placebo (n = 12)		Rebamipide (n = 12)		P value
Gastrointestinal symptom	Before	After	Before	After	Before	After
Any	3	5	5	3	0.67	0.33
Abdominal pain	2	3	3	2	0.50	0.50
Heartburn	2	2	3	1	0.50	0.50
Nausea	1	2	1	1	0.76	0.50
Intestinal cramps	0	1	1	0	0.50	0.50
Fullness	1	0	0	0	0.50	1.00

Incidence of gastrointestinal symptoms in each treatment group before the beginning and at the end of the study. P value was calculated comparing incidence of symptoms between placebo and rebamipide groups before and after treatments by Fisher’s exact test

ISSN: 1471-230X